Johnson & Johnson Makes Significant Investment In Arrowhead Hepatitis B Treatment.

Reuters (10/4, Mathias) reports Johnson & Johnson agreed to develop and market Arrowhead Pharmaceutical’s “gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion.” J&J’s Janssen Pharmac...